Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Research & Development (2020 - 2025)

Historic Research & Development for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $5.9 million.

  • Ovid Therapeutics' Research & Development fell 2527.05% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year decrease of 3992.43%. This contributed to the annual value of $36.8 million for FY2024, which is 2860.99% up from last year.
  • Latest data reveals that Ovid Therapeutics reported Research & Development of $5.9 million as of Q3 2025, which was down 2527.05% from $6.5 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Research & Development peaked at $18.1 million during Q4 2021, and registered a low of $4.9 million during Q3 2021.
  • Moreover, its 5-year median value for Research & Development was $6.6 million (2023), whereas its average is $8.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 6928.51% in 2022, then skyrocketed by 10973.5% in 2024.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Research & Development stood at $18.1 million in 2021, then tumbled by 69.29% to $5.6 million in 2022, then surged by 91.53% to $10.6 million in 2023, then crashed by 44.34% to $5.9 million in 2024, then fell by 0.89% to $5.9 million in 2025.
  • Its Research & Development stands at $5.9 million for Q3 2025, versus $6.5 million for Q2 2025 and $6.7 million for Q1 2025.